Home Metabolism CETP

CETP Inhibitors

CETP Products

  • All (5)
  • CETP Inhibitors (5)
  • New CETP Products
Cat.No. Product Name Information Product Use Citations Product Validations
S2748 Anacetrapib (MK-0859) Anacetrapib (MK-0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM. It increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure, and is in Phase 3.
Circulation, 2021, 143(9):921-934
J Phys Chem B, 2016, 120(33):8254-63
Atherosclerosis, 2014, 235(2):449-62
S2772 Dalcetrapib (JTT-705) An inhibitor of rhCETP with an IC50 of 0.2 μM, Dalcetrapib (JTT-705) increases plasma HDL cholesterol. Phase 3.
Atherosclerosis, 2014, 235(2):449-62
S2792 Torcetrapib Torcetrapib (CP-529414) is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3.
J Immunother Cancer, 2024, 12(11)e009805
S2925 Evacetrapib (LY2484595) Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3.
E1561New Obicetrapib Obicetrapib (TA-8995, AMG-899, DEZ-001) is an inhibitor of Cholesteryl Ester Transfer Protein (CETP) that significantly reduces non-HDL cholesterol (non-HDL-C) and lipoprotein(a) levels while increasing high-density lipoprotein cholesterol (HDL-C). It also has the potential to reduce major adverse cardiovascular events.
S2748 Anacetrapib (MK-0859) Anacetrapib (MK-0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM. It increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure, and is in Phase 3.
Circulation, 2021, 143(9):921-934
J Phys Chem B, 2016, 120(33):8254-63
Atherosclerosis, 2014, 235(2):449-62
S2772 Dalcetrapib (JTT-705) An inhibitor of rhCETP with an IC50 of 0.2 μM, Dalcetrapib (JTT-705) increases plasma HDL cholesterol. Phase 3.
Atherosclerosis, 2014, 235(2):449-62
S2792 Torcetrapib Torcetrapib (CP-529414) is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3.
J Immunother Cancer, 2024, 12(11)e009805
S2925 Evacetrapib (LY2484595) Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3.
E1561New Obicetrapib Obicetrapib (TA-8995, AMG-899, DEZ-001) is an inhibitor of Cholesteryl Ester Transfer Protein (CETP) that significantly reduces non-HDL cholesterol (non-HDL-C) and lipoprotein(a) levels while increasing high-density lipoprotein cholesterol (HDL-C). It also has the potential to reduce major adverse cardiovascular events.
E1561New Obicetrapib Obicetrapib (TA-8995, AMG-899, DEZ-001) is an inhibitor of Cholesteryl Ester Transfer Protein (CETP) that significantly reduces non-HDL cholesterol (non-HDL-C) and lipoprotein(a) levels while increasing high-density lipoprotein cholesterol (HDL-C). It also has the potential to reduce major adverse cardiovascular events.

Signaling Pathway Map